Yiming Liu


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Yiming Liu specializes in representing companies and investment funds with mergers and acquisitions and other strategic transactions across multiple industries, including life sciences and high-tech industries. He is uniquely positioned to leverage his technical background—with advanced degrees in molecular, cellular and developmental biology and health services administration—to help clients achieve results that make practical and commercial sense. On behalf of clients in the United States, Europe and China, he has successfully led the structuring, negotiation and documentation of a wide range of cross-border transactions involving critical intellectual property, including mergers and acquisitions, private financings, joint ventures, research collaborations and licensing arrangements.

In addition to his track record executing complex corporate and commercial transactions, Yiming is also recognized for his work on life sciences and high-tech IPOs and other public market transactions in Hong Kong and the United States, experience which is invaluable for both public company clients and clients considering an initial public offering.

Prior to joining O’Melveny, Yiming practiced in the New York and Shanghai offices of two other leading U.S. law firms.


  • English
  • Mandarin Chinese


  • New York


  • Columbia University, J.D.
  • University of Michigan, M.S. (Molecular, Cellular, and Developmental Biology); M.H.S.A. (Health Services Administration)
  • Fudan University, B.S. (Biological Sciences)

Mergers & Acquisitions

  • Apex Technology as a lead member of a consortium in the US$4 billion acquisition of Lexmark International Inc., a Lexington, Kentucky-based company that develops and manufactures laser printers and imaging products. The consortium also included PAG Asia Capital and Legend Capital
  • BATS Global Markets, a leading global stock exchange operator based in Kansas, in its US$365 million acquisition of Hotspot FX, a leading institutional spot foreign exchange market, from New Jersey-based financial services firm KCG Holdings Inc.
  • ByteDance (Toutiao) in leading a private financing round of India's news and content aggregator DailyHunt that raised US$25 million
  • Didi Chuxing in its acquisition of and merger with Uber China, and in its private financing round that raised more than US$5.5 billion from a consortium led by SoftBank to support its global strategy and development of artificial intelligence-based technologies
  • HUYA Inc., a game live streaming platform in China, in its US$461.6 million investment by Tencent
  • JD.com and JD Finance in the US$500 million joint ventures for e-commerce and fintech services in Thailand with Thailand's largest retail conglomerate Central Group and Provident Capital
  • JHL Biotech in the spin-off and US$125 million private financing of its CDMO business division
  • Mitsubishi UFJ Lease & Finance in its US$370 million acquisition of Engine Lease Finance Corporation and Beacon Intermodal Leasing from The Bank of Tokyo Mitsubishi UFJ, Ltd.
  • Roche in its research collaboration and licensing arrangements with, and purchase of an option to acquire, Janus Biotherapeutics, a Boston-based biopharmaceutical company, for the development of a small molecule toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases
  • Roche in its proposed acquisition of a U.S.-based clinical-stage biopharmaceutical company and its pipeline assets
  • Roper Technologies, a U.S. diversified industrial company, in its acquisition of Illinois-based RF IDeas, Inc., a leading provider of proprietary identification card technology solutions, which was one of two concurrently announced acquisitions with a combined purchase price of US$277 million
  • Shire in matters related to its US$325 million acquisition of FerroKin BioSciences and its Phase 2 candidate deferitazole, a small molecule iron chelator for the treatment of transfusional iron overload

Private Equity

  • A leading China-based private equity firm in its investment in a joint venture set up by a global pharmaceutical and medical device company and a major academic medical center in the U.S. to co-develop and deliver novel clinical diagnostic services in China
  • CITIC PE in its proposed investment in a Hong Kong medical device company
  • Crestview Partners in various private equity transactions in the U.S., including the investment in its portfolio company Key Safety Systems, a Michigan-based company that develops and manufactures automotive safety systems, by FountainVest Partners
  • Tailwind Capital in the sale of ReTrans Inc., a leading U.S. non-asset brokerage provider of intermodal transportation, to Switzerland-based Kühne + Nagel, one of the world's leading logistics companies with a focus on providing information technology-based integrated logistics solutions